Workflow
BPSemi(688368)
icon
Search documents
晶丰明源: 上海晶丰明源半导体股份有限公司关于聘任董事会秘书的公告
Zheng Quan Zhi Xing· 2025-08-26 11:08
邮政编码:201203 联系电话:021-50278297 证券代码:688368 证券简称:晶丰明源 公告编号:2025-066 上海晶丰明源半导体股份有限公司 关于聘任董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 上海晶丰明源半导体股份有限公司(以下简称"公司")董事会于 2025 年 会秘书的议案》。经公司董事长提名,董事会提名委员会对被提名人进行资格审 查,董事会同意聘任杨彪先生为公司董事会秘书(简历后附),任期自本次董事 会审议通过之日起至公司第三届董事会任期届满之日止。公司董事长、总经理胡 黎强先生不再代行董事会秘书职责。 杨彪先生已取得上海证券交易所科创板董事会秘书任职培训证明,具备履行 董事会秘书职责所需的专业知识及工作经验,其任职资格符合有关法律法规及规 范性文件的规定,不存在《中华人民共和国公司法》(以下简称"《公司法》") 《上海证券交易所科创板股票上市规则》及《公司章程》等规定的不得担任上市 公司高级管理人员的情形。 杨彪先生联系方式如下: 联系地址:中国(上海)自由贸易试验区申 ...
【机构调研记录】国泰基金调研兆易创新、特宝生物等10只个股(附名单)
Sou Hu Cai Jing· 2025-08-26 00:06
Group 1: Zhaoyi Innovation - Zhaoyi Innovation reported good growth across all business lines in Q2 2024, with NOR Flash growing in the high single digits, niche DRAM growing over 50%, and MCU close to 20% [1] - The company expects significant revenue growth in niche DRAM in the second half of the year, with contract prices continuing to rise [1] - The demand for NOR Flash is increasing due to a rise in electronic product code volume, while supply remains tight due to wafer manufacturing capacity constraints [1] Group 2: Teabo Bio - Teabo Bio is focusing on functional cure for hepatitis B through a combination of different mechanism drugs with interferons and nucleoside analogs [2] - The company aims to provide comprehensive management of hepatitis B through a wide-reaching clinical cure network [2] - Collaboration with Ligos is underway to explore reinfection control after clearing infected cells [2] Group 3: Ruijie Networks - Ruijie Networks saw significant revenue growth in data center products, primarily driven by internet clients, with over 90% of revenue coming from this sector [3] - The company anticipates continued strong demand for cloud computing infrastructure in the second half of the year [3] - The gross margin for data center products is relatively low (15%-20%), while margins in enterprise and SMB markets have improved [3] Group 4: Trina Solar - Trina Solar is focusing on maintaining fair competition in the photovoltaic industry and promoting healthy development [4] - The company aims for over 8GWh in the storage segment for the year, with an increasing proportion of overseas orders [4] - The demand in the U.S. market is accelerating, leading to increased component prices and optimized supply chains [4] Group 5: Liangxin Co. - Liangxin Co. has segmented its data center business into three main areas: internet enterprises, operators, and individual projects, with a focus on HVDC and UPS [5] - The company is expected to continue its efforts in digital energy and infrastructure despite a potential slowdown in the renewable energy sector [5] - The gross margin for overseas business has slightly decreased compared to the previous year [5] Group 6: Baillie Tianheng - Baillie Tianheng is advancing three key overseas clinical trials for treating triple-negative breast cancer, EGFR-mutant non-small cell lung cancer, and urothelial carcinoma [6] - The company has submitted its first nuclear medicine candidate drug for domestic IND application [6] - R&D expenses reached 1.038 billion yuan by mid-year, with expectations for future clinical research costs to increase [6] Group 7: Jingfeng Mingyuan - Jingfeng Mingyuan has achieved an increase in overall gross margin through cost reduction and efficiency improvements [7] - The company is expanding its market presence in smart LED lighting products despite a decline in sales and prices in traditional LED lighting [7] - The high-performance computing power supply chip business has seen rapid growth, with products entering large-scale sales [7] Group 8: Chipone - Chipone is providing various customized hardware and software solutions in the AI field, serving multiple international giants [8] - The company has a high percentage of R&D personnel, with 89.31% of staff engaged in research and development [8] - Chipone is advancing Chiplet technology and has achieved success in designing high-performance automotive chips [8] Group 9: Xiasha Precision - Xiasha Precision reported a 30.77% increase in revenue for the first half of 2025, but a 41.87% decline in net profit due to price competition and rising costs [9] - The company plans to expand its product line in joint modules and increase R&D investment [9] - A new factory in Vietnam is under trial production, with plans to expand into overseas markets [9] Group 10: Lepu Medical - Lepu Medical's subsidiary focuses on elderly care services and has developed a facial filler product that has received regulatory approval [10] - The company is advancing AI products that monitor vital signs through various hardware applications [10] - Lepu Medical has a significant asset management scale, ranking 14th among 210 in public fund management [10]
晶丰明源股价微涨0.01% 半年度净利润同比上升151.67%
Jin Rong Jie· 2025-08-25 18:44
从资金流向来看,8月25日主力资金净流入935.10万元,占流通市值的0.1%。近五日主力资金累计净流 出3710.88万元,占流通市值的0.41%。 风险提示:投资有风险,入市需谨慎。本文所载信息仅供参考,不构成投资建议。 晶丰明源主营业务为模拟及混合信号集成电路的研发、设计和销售。公司产品广泛应用于LED照明、家 电、电源管理等领域。2025年半年度报告显示,公司实现销售收入7.31亿元,归属于上市公司股东的净 利润1576.20万元,较上年同期增加4626.96万元,同比上升151.67%。 8月25日公司发布公告称,在8月18日至22日期间接待了中信建投证券、交银基金、国泰基金等多家机构 调研。调研内容主要围绕公司半年度业绩情况展开。数据显示,近一年来公司共接待403家机构641次调 研。 截至2025年8月25日收盘,晶丰明源股价报102.59元,较前一交易日上涨0.01元,涨幅0.01%。当日开盘 价为104.24元,最高触及106.58元,最低下探101.91元,成交量为31799手,成交额达3.30亿元。 ...
近33亿!晶丰明源出手!
是说芯语· 2025-08-25 02:41
Core Viewpoint - The article discusses the acquisition of Easy Charge Technology by Shanghai Jingfeng Mingyuan Semiconductor Co., Ltd. for 3.283 billion RMB (approximately 457 million USD) to enhance its product portfolio and competitiveness in the semiconductor industry [3][8]. Group 1: Company Overview - Shanghai Jingfeng Mingyuan, established in 2008, specializes in power management and control driver chips, with applications in various sectors including home appliances, mobile phones, and automotive [5][7]. - Easy Charge Technology, founded in 2016, is a leading provider of power management solutions, focusing on high-performance analog chips and mixed-signal integrated circuits, including wireless charging chips [5][10]. Group 2: Acquisition Details - The acquisition aims to strengthen Jingfeng Mingyuan's position in the "hard technology" sector and enhance its international competitiveness by integrating Easy Charge's resources [8][19]. - The transaction is characterized by a high premium, with an estimated valuation of Easy Charge at 3.29 billion RMB, reflecting a premium rate of 260.08% [16][17]. Group 3: Financial Performance - Easy Charge has reported losses in recent years, with projected losses of 502 million RMB and 512 million RMB for 2023 and 2024, respectively, totaling over 1 billion RMB in losses [14][16]. - Jingfeng Mingyuan has also faced profitability challenges, with net losses reported in the past three years, although it achieved a revenue of 1.504 billion RMB in 2024, a year-on-year increase of 15.38% [18]. Group 4: Strategic Implications - The acquisition is expected to enhance product offerings in wireless charging and automotive electronics, leveraging Easy Charge's established customer base, including major brands like Samsung and BYD [19][20]. - Performance commitments have been set for Easy Charge's business segments from 2025 to 2027, ensuring minimum net profits and revenues, which may provide a framework for long-term value realization [20][21].
社保基金现身29只科创板股前十大流通股东榜
Core Insights - The Social Security Fund has disclosed its stock holdings as of the end of Q2, appearing in the top ten shareholders of 29 stocks on the Sci-Tech Innovation Board, with a total holding of 94.71 million shares valued at 4.23 billion yuan [1][2] Group 1: Stock Holdings - The Social Security Fund has newly entered 6 stocks and increased holdings in 8 stocks, while reducing holdings in 7 stocks, with 8 stocks remaining unchanged [1] - The stocks with the highest holdings by the Social Security Fund include Daotong Technology with 9.27 million shares, followed by Times Electric and ST Nuotai with 6.31 million and 5.72 million shares respectively [2][3] - The highest holding ratio is for Haitai Xinguang at 4.20%, followed by Aopumai at 4.00% [2] Group 2: Financial Performance - Among the stocks held by the Social Security Fund, 25 companies reported year-on-year net profit growth in the first half of the year, with Rongzhi Rixin showing the highest growth rate of 2063.42% [2] - Other notable profit growth includes Xinxing Microelectronics and Jingfeng Mingyuan, with increases of 261.78% and 151.67% respectively [2] Group 3: Market Performance - Stocks held by the Social Security Fund on the Sci-Tech Innovation Board have averaged a 22.67% increase since July [3] - The best-performing stock is Dingtong Technology, with a cumulative increase of 69.16%, followed by Yuandong Biology and Kaiyin Technology with increases of 54.02% and 39.07% respectively [3]
晶丰明源(688368) - 上海晶丰明源半导体股份有限公司发行股份及支付现金购买资产并募集配套资金报告书(草案)摘要(修订稿)
2025-08-19 16:02
购买资产并募集配套资金报告书(草案) 摘要(修订稿) | 项目 | 交易对方 | | --- | --- | | 发行股份及支付 | 海南玮峻思投资合伙企业(有限合伙)等 名易冲科 50 | | 现金购买资产 | 技股东 | | 募集配套资金 | 不超过 35 名符合中国证监会规定的特定投资者 | 独立财务顾问 签署日期:二〇二五年八月 声 明 股票代码:688368 股票简称:晶丰明源 上市地点:上海证券交易所 上海晶丰明源半导体股份有限公司 发行股份及支付现金 本部分所述词语或简称与报告书摘要"释义"所述词语或简称具有相同含义。 一、上市公司声明 本公司及本公司全体董事、监事及高级管理人员保证上市公司及时、公平地披露 信息,保证报告书及其摘要内容的真实、准确、完整,不存在虚假记载、误导性陈述 或者重大遗漏,保证报告书所引用的相关数据的真实性和合理性,并对所提供信息的 真实性、准确性、完整性负相应的法律责任。 如本次交易所披露或提供的信息涉嫌虚假记载、误导性陈述或者重大遗漏,被司 法机关立案侦查或者被中国证监会立案调查的,在形成调查结论以前,不转让在该上 市公司拥有权益的股份,并于收到立案稽查通知的两个交易 ...
晶丰明源(688368) - 上海晶丰明源半导体股份有限公司发行股份及支付现金购买资产并募集配套资金报告书(草案)(修订稿)
2025-08-19 16:02
股票代码:688368 股票简称:晶丰明源 上市地点:上海证券交易所 发行股份及支付现金 购买资产并募集配套资金报告书(草案) (修订稿) | 发行股份及支付 | 海南玮峻思投资合伙企业(有限合伙)等 50 名易冲科 | | --- | --- | | 现金购买资产 | 技股东 | | 募集配套资金 | 不超过 35 名符合中国证监会规定的特定投资者 | 独立财务顾问 签署日期:二〇二五年八月 上海晶丰明源半导体股份有限公司 项目 交易对方 上海晶丰明源半导体股份有限公司发行股份及支付现金购买资产并募集配套资金报告书(草案)(修订稿) 声 明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 中国证监会、上交所对本次交易所作的任何决定或意见均不代表其对本公司股票 的价值或投资者收益的实质性判断或保证。 根据《证券法》等相关法律、法规的规定,本次交易完成后,本公司经营与收益 的变化,由本公司自行负责,由此变化引致的投资风险,由投资者自行负责。投资者 在评价公司本次交易时,除本报告书内容以及与本报告书同时披露的相关文件外,还 应认真地考虑本报告书披露的各项风险因素。投资者若对本报告书存在任何疑问 ...
晶丰明源(688368) - 立信会计师事务所(特殊普通合伙)关于上海晶丰明源半导体股份有限公司发行股份及支付现金购买资产并募集配套资金申请文件审核问询函的回复
2025-08-19 16:02
信会师函字[2025]第 ZA388 号 上海证券交易所: 贵所出具的《关于上海晶丰明源半导体股份有限公司发行股份及支付现金购 发行股份及支付现金购买资产并募集配套资金申请文件 审核问询函的回复 买资产并募集配套资金申请的审核问询函》(上证科审(并购重组)〔2025〕21 号)(以下简称"《问询函》")已收悉,立信会计师事务所(特殊普通合伙)(以 下简称"会计师")对相关问题逐项进行了认真核查,现将核查过程和核查意见回 复如下。 6-3-1 关于上海晶丰明源半导体股份有限公司 问题三、关于差异化定价 根据重组报告书:(1)本次交易共有 50 名交易对方,其中 7 个交易对方 进行了业绩承诺,部分员工持股平台未参与业绩承诺;(2)本次交易采用差异 化定价,42 个财务投资人基于"保本"的逻辑进行定价,其余 8 个管理层及员 工持股平台基于标的公司 100%股权评估值与其他投资人交易对价"差额"进行 协商定价;(3)智合聚德为标的公司境外核心人员持股平台,考虑到其对标的 公司的贡献,交易对价高于其余管理层及员工持股平台,全部取得现金对价, 且未参与业绩承诺;(4)玮峻思为标的公司管理层持股平台,其交易对价系基 于 ...
晶丰明源(688368) - 关于上海晶丰明源半导体股份有限公司发行股份及支付现金购买资产并募集配套资金申请的审核问询函的回复
2025-08-19 16:02
关于上海晶丰明源半导体股份有限公司 发行股份及支付现金购买资产并募集配套资金 申请的审核问询函的回复 独立财务顾问 签署日期:二〇二五年八月 上海证券交易所: 按照贵所下发的《关于上海晶丰明源半导体股份有限公司发行股份及支付现 金购买资产并募集配套资金申请的审核问询函》(上证科审(并购重组)〔2025〕 21 号)(以下简称"审核问询函")的要求,上海晶丰明源半导体股份有限公 司(以下简称"公司"、"上市公司"或"晶丰明源")及相关中介机构就审核 问询函所提问题进行了认真讨论分析,现将相关回复说明如下。 本审核问询函回复(以下简称"本回复")中的报告期指 2023 年、2024 年; 除此之外,如无特别说明,本回复所述的词语或简称与重组报告书中"释义"所 定义的词语或简称具有相关的含义。在本回复中,若合计数与各分项数值相加之 和在尾数上存在差异,均为四舍五入所致。本回复所引用的财务数据和财务指标, 如无特殊说明,指合并报表口径的财务数据和根据该类财务数据计算的财务指标。 | 审核问询函所列问题 | 黑体(加粗) | | --- | --- | | 审核问询函所列问题的回复、对重组报告书的引用 | 宋体 | | ...
晶丰明源(688368) - 金证(上海)资产评估有限公司关于上海证券交易所《关于上海晶丰明源半导体股份有限公司发行股份及支付现金购买资产并募集配套资金申请的审核问询函》资产评估相关问题回复之核查意见
2025-08-19 16:02
金证(上海)资产评估有限公司 关于上海证券交易所《关于上海晶丰明源半导体股份有限公司发 行股份及支付现金购买资产并募集配套资金申请的审核问询函》 (上证科审(并购重组)〔2025〕21 号) 资产评估相关问题回复之核查意见 金证(上海)资产评估有限公司 二〇二五年八月 上海证券交易所: 按照贵所下发的《关于上海晶丰明源半导体股份有限公司发行股份及支付现金购 买资产并募集配套资金申请的审核问询函》(上证科审(并购重组)〔2025〕21 号)(以 下简称"审核问询函")的要求,金证(上海)资产评估有限公司(以下简称"金证评估") 作为本次交易的资产评估机构,已会同上市公司及各中介机构,就审核问询函要求评 估师核查的内容进行了认真讨论分析及落实,现将相关问题做出书面回复如下,请予 审核。 问题一(原问题五)、关于市场法评估 根据重组报告书:(1)本次交易最终选用市场法评估结果作为本次评估结论,市 场法估值 329,000.00 万元,增值率为 260.08%,资产基础法评估值为 285,243.11 万元, 增值率 212.19%,市场法评估结果与资产基础法评估结果差异 43,756.89 万元,差异率 为 15. ...